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Abstract
Background: Candida species have various degrees of susceptibility to common antifungal drugs.
The extent of resistance to amphotericin B and fluconazole of Candida glabrata isolates causing
candidemia has been reported. Active surveillance may help us to monitor the trend of
susceptibility to antifungal drugs and to determine if there is an emerging co-resistance to both
drugs of Candida species, specifically, of C. glabrata in Taiwan.
Methods: The susceptibilities to amphotericin B and fluconazole of Candida species collected in
1999 and 2002 of the Taiwan Surveillance of Antimicrobial Resistance of Yeasts (TSARY) were
determined by the microdilution method.
Results:  The antifungal susceptibilities of 342 and 456 isolates collected from 11 hospitals
participating in both TSARY 1999 and TSARY 2002, respectively, have been determined. The
resistance rate to amphotericin B has increased from 0.3% in the TSARY1999 to 2.2% in the TSARY
2002. In contrast, the resistance rate to fluconazole has decreased from 8.8% to 2.2%.
Nevertheless, significantly more C. glabrata isolates were not susceptible to fluconazole in the
TSARY 2002 (47.4%) than that in the TSARY 1999 (20.8%). There were 9.8% and 11% of C. glabrata
isolates having susceptible-dose dependent and resistant phenotype to fluconazole in the TSARY
1999, verse 45.3% and 2.1% in the TSARY 2002.
Conclusion: There was an increase of resistance rate to amphotericin B in C. glabrata. On the
other hand, although the resistance rate to fluconazole has decreased, almost half of C. glabrata
isolates were not susceptible to this drug. Hence, continuous monitoring the emerging of co-
resistance to both amphotericin B and fluconazole of Candida species, specifically, of C. glabrata, will
be an important early-warning system.
Background
In the past decade, nosocomial yeast infections have
increased globally. In Taiwan, the prevalence of nosoco-
mial candidemia increased 16-fold from 1981 through
Published: 03 November 2005
BMC Infectious Diseases 2005, 5:99 doi:10.1186/1471-2334-5-99
Received: 08 March 2005
Accepted: 03 November 2005
This article is available from: http://www.biomedcentral.com/1471-2334/5/99
© 2005 Yang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2005, 5:99 http://www.biomedcentral.com/1471-2334/5/99
Page 2 of 5
(page number not for citation purposes)
1993 [1,2]. In the United States, yeast infections rank as
the fourth most common cause of nosocomial blood-
stream infection [3,4]. Furthermore, candidemia contrib-
ute considerable mortality (31% to 38%), extend the
length of hospital stay [5,6], and increase social cost due
to lost productivity and disabling complications [7]. Con-
sequently, the Taiwan Surveillance of Antimicrobial
Resistance of Yeasts (TSARY) was initiated in 1999 for epi-
demiological study of yeast infections in Taiwan [8,9]
Candida species have various degrees of susceptibility to
common antifungal agents. Candida lusitaniae is less sus-
ceptible to amphotericin B [10] while Candida krusei and
Candida glabrata are less susceptible to fluconazole than
other Candida species [11-14]. The extent of fluconazole
resistance of C. glabrata isolates causing candidemia has
been reported throughout the United States [15]. Further-
more, C. glabrata exhibits variable cross-resistance to the
other triazoles, such as voriconazole and posaconazole
[13,16-18] and amphotericin B became the next choice.
The aim of this study is to investigate the trend of suscep-
tibility to amphotericin B and fluconazole of Candida spe-
cies in Taiwan from 1999 to 2002. Especially, we would
like to determine if there is an emerging co-resistance to
amphotericin B and fluconazole of Candida species, spe-
cifically, of C. glabrata, in Taiwan.
Methods
Organisms and media
Yeast isolates were collected from 11 hospitals participat-
ing in both TSARY 1999 and TSARY 2002 [9,19]. Isolates
were stored frozen at -70°C in bead containing Micro-
bank cryovials (PRO-LAB Diagnostics, Austin, TX, USA).
At the end of the collection period, isolates were kept fro-
zen and transported by an express delivery company to
the laboratory at National Health Research Institutes
(NHRI) within 24 hours. After their arrival, the isolates
were first sub-cultured on to sabouraud dextrose agar
(SDA, BBL, Becton Dickinson Cockeysville, MD, USA) to
check for purity and identifications. Pure isolates were
labeled and stored in vials containing 50% glycerol at -
70°C for subsequent analyses.
Identification
The identification procedure of yeast isolates in the NHRI
laboratory was performed as described previously [8]. In
general, isolates identified as C. albicans by hospitals were
first subjected to the germ tube assay in brain heart infu-
sion (BHI, BBL) medium containing 10% fetal bovine
serum (JR12003, JRH Biosciences, Australia) at 37°C for
2–3 hours [20]. Isolates positive in germ tube assay were
checked for growth at 42°C to differentiate C. albicans
from C. dubliniensis [21]. The VITEK Yeast Biochemical
Table 1: The Susceptibilities of Candida Species to Amphotericin B
TSARY 1999 
MIC µg/ml
cal ctr cgl cpa ckr Others Total
 0.25 19 (14.7)a 5 (5.1) 5 (6.1) 5 (22.7) 0 3 (42.8) 37 (10.8)
0.5 81 (62.8) 57 (58.2) 52 (63.4) 8 (36.4) 1 (25) 2 (28.6) 201 (58.8)
1 29 (22.5) 36 (36.7) 25 (30.5) 9 (40.9) 2 (50) 2 (28.6) 103 (30.1)
20000 1  ( 2 5 ) 0 1  ( 0 . 3 )
Total 129 98 82 22 4 7 342
MIC50 µg/ml 0.5 0.5 0.5 0.5 1.0 0.5 0.5
MIC90 µg/ml 1.0 1.0 1.0 1.0 2.0 1.0 1.0
TSARY 2002 
MIC µg/ml
cal ctr cgl cpa ckr Others Total
 0.25 8 (4.2) 1 (0.8) 0 3 (8.3) 0 0 12 (2.6)
0.5 122 (64.9) 70 (54.2) 17 (17.9) 17 (47.2) 1 (20) 1 (33.3) 228 (50)
1 56 (29.8) 57 (44.2) 75 (78.9) 16 (44.5) 0 2 (66.7) 206 (45.2)
2 2 (1.1) 1 (0.8) 3 (3.2) 0 4 (80) 0 10 (2.2)
Total 188 129 95 36 5 3 456
MIC50 µg/ml 0.5 0.5 1 0.5 2 1 0.5
MIC90 µg / m l 1111211
cal, C. albicans; ctr, C. tropicalis; cgl, C. glabrata; cpa, C. parapsilosis; ckr, C. krusei
anumber of isolates (%)BMC Infectious Diseases 2005, 5:99 http://www.biomedcentral.com/1471-2334/5/99
Page 3 of 5
(page number not for citation purposes)
Card (YBC, bioMerieux, St. Louis, MI, USA) was then used
to analyze isolates appearing to be negative by the germ
tube assay in the NHRI laboratory and isolates identified
as non-albicans Candida species by the hospitals. API-
32C (bioMerieux) was used to assess the NHRI result
when the VITEK-YBC showed less than 90% confidence.
Antifungal susceptibility testing
The minimum inhibitory concentration (MIC) to ampho-
tericin B or fluconazole of each yeast isolate was deter-
mined by in vitro antifungal susceptibility testing
according to the guidelines by the Clinical and Laboratory
Standards Institute (CLSI, formerly NCCLS) [22]. The
RPMI medium 1640 (31800-022, Invitrogen Corpora-
tion, Carlsbad, CA, USA) was used for dilution. Several
strains from American Type Culture Collection, namely,
ATCC 14053 C. albicans, ATCC 9003 C. glabrata, ATCC
6258 C. krusei, and ATCC20019 Candida parapsilosis
were used as controls. The growth of each isolate was
measured by a Spectra MAX Plus (Molecular Devices Cop.
Sunnyvale, California, USA) after 48-hour incubation at
35°C. We also measured the MICs of some randomly-
sampled isolates by Etest (AB Biodisk Solna, Sweden) to
confirm our results by microdilution.
The interpretation of MICs was conducted according to
the guidelines of the CLSI. The MICs to amphotericin B
and fluconazole were defined as the lowest concentration
of amphotericin B and fluconazole to reduce the turbidity
of cells to greater than 95% and 50%, respectively. For
amphotericin B, isolates with MIC  2 µg/ml were consid-
ered to be resistant, whereas those with MIC  1 µg/ml
were susceptible. For fluconazole, isolates with MIC  64
µg/ml were considered resistant, while those with MIC 
8 µg/ml were susceptible. Isolates with MICs between 16
and 32 µg/ml were susceptible-dose dependent. The MICs
of 50% and 90% of the total population were defined as
MIC50 and MIC90. For any species with less than ten, the
MIC50 and MIC90 were not showed.
Database and analysis
The database for this study contained the following char-
acteristic information of each submitted isolate: hospital
origin, location and type of the hospital, identification
and source of the isolate. The statistic significance of the
differences in frequencies and proportions was deter-
mined by the chi-square test with Yates' correction. A p
value of  0.05 was considered statistically significant.
Results
Distribution of Candida species
The distribution of Candida species was similar in both
surveys. Candida albicans was the most common species
consisting 37.7% of the total isolates in the TSARY 1999
and 41.2% in the TSARY 2002. Candida tropicalis (28.7%
in 1999 vs. 28.3% in 2002) and C. glabrata (24% in 1999
vs. 20.8% in 2002) were the two most common non-albi-
cans Candida species, followed by C. parapsilosis (6.4%
in 1999 vs. 7.9% in 2002), C. krusei (1.2% in 1999 vs.
1.1% in 2002), and others (2% in 1999 vs. 0.7% in 2002).
When classified according to the sources, isolates from
urine, sputum, blood, wound, and others were 143
Table 2: The Susceptibilities of Candida Species to Fluconazole
TSARY 1999 
MIC µg/ml
cal ctr cgl cpa ckr Others Total
S 121 (93.8)a 77 (78.6) 65 (79.2) 21 (95.5) 0 5 (71.4) 289 (84.5)
SDD 3 (2.3) 9 (9.2) 8 (9.8) 1 (4.5) 0 2 (28.6) 23 (6.7)
R 5 (3.9) 12 (12.2) 9 (11) 0 4 (100) 0 30 (8.8)
Total 129 98 82 22 4 7 342
MIC50 µg/ml 0.25 2 4 1 ND ND 2
MIC90 µg/ml 4 64 64 4 ND ND 16
TSARY 2002 
MIC µg/ml
cal ctr cgl cpa ckr Others Total
S 178 (94.7) 124 (96.1) 50 (52.6) 36 (100) 1 (20) 2 (66.7) 391 (85.8)
SDD 6 (3.2) 5 (3.9) 43 (45.3) 0 1 (20) 0 55 (12)
R 4 (2.1) 0 2 (2.1) 0 3 (60) 1 (33.3) 10 (2.2)
Toal 188 129 95 36 5 3 456
MIC50 µg/ml 0.25 1 8 1 ND ND 1
MIC90 µg/ml 1 4 32 2 ND ND 16
cal, C. albicans; ctr, C. tropicalis; cgl, C. glabrata; cpa, C. parapsilosis; ckr, C. krusei
anumber of isolates (%), S, susceptible; SDD, susceptible-dose dependent; R, resistant ND, not showed due to small number of isolatesBMC Infectious Diseases 2005, 5:99 http://www.biomedcentral.com/1471-2334/5/99
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(41.8%), 101 (29.5%), 30 (8.8%), 26 (7.6%), and 42
(12.3%), respectively, in the TSARY 1999 verse 186
(40.8%), 111 (24.3%), 50 (11%), 20 (4.4%), and 89
(19.5%), respectively, in the TSARY 2002.
Susceptibilities to amphotericin B
The susceptibilities to amphotericin B are shown in Table
1. A total of 10 isolates (2.2%) were resistant to ampho-
tericin B in the TSARY 2002, whereas only one (0.3%) in
the TSARY 1999 (p < 0.05). Of these 11 amphotericin B
resistant isolates, 9 were non-albicans Candida species,
including 5 C. krusei, 3 C. glabrata, and 1 C. tropicalis. In
general, C. krusei was less susceptible to amphotericin B
than other species.
Susceptibilities to fluconazole
The susceptibilities to fluconazole of Candida species are
shown in Table 2. In the TSARY 1999, a total of 289
(84.5%), 23 (6.7%), and 30 (8.8%) isolates were suscep-
tible, susceptible-dose dependent, and resistant to fluco-
nazole, respectively, whereas in the TSARY 2002, there
were 391 (85.5%), 55 (12%), and 10 (2.2%). The MIC50
and MIC90 of these isolates in the TSARY1999 were 2 µg/
ml and 16 µg/ml, respectively, and in the TSARY 2002,
they were 1 µg/ml and 16 µg/ml. In the TSARY 1999, 12
(12.2%) C. tropicalis, 9 (11%) C. glabrata, 5 (3.9%) C.
albicans, and 4 (100%) C. krusei, while in the TSARY
2002, 4 (2.1%) C. albicans, 3 (60%) C. krusei, and 2
(2.1%) C. glabrata were resistant to fluconazole. Fewer
isolates in the TSARY 2002 were resistant to fluconazole
than that in the TSARY 1999 (p < 0.05). In contrast, more
isolates from the TSARY 2002 were susceptible-dose
dependent than that in the TSARY 1999 (p < 0.05). Con-
sequently, there were similar portions of isolates suscepti-
ble to fluconazole in both surveys. Nevertheless, there
were less isolates with MICs  2 µg/ml to fluconazole in
the TSARY 1999 (71.6%, 207/289) than in the TSARY
2002 (81.8%, 320/391) (p < 0.05). Finally, in the TSARY
1999, 82 (24%) of isolates had MICs between 4 and 8 µg/
ml to fluconazole. It was down to 71 (15.6%) in the
TSARY 2002.
Discussion
The trend of susceptibilities to antifungal drugs of Candida
species from 1999 to 2002 has been determined in this
study. As expected, C. krusei had the highest resistance rate
to fluconazole among Candida  species tested, which is
consistent with previous reports [9,11]. In contrast, all C.
parapsilosis isolates were susceptible to fluconazole, which
is also consistent with previous reports that C. parapsilosis
is the most susceptible species to fluconazole
[9,18,23,24]. Though the overall resistance rate to fluco-
nazole has decreased from 8.8% to 2.2%, there were sig-
nificantly more C. glabrata isolates not susceptible to
fluconazole in the TSARY 2002 than that in the TSARY
1999. Overexpression of CgCDR1,  CgCDR2, and
CgSNQ2-encoded efflux pumps has been shown to be a
major mechanism contributing to the drug resistance [25-
27]. It would be interesting to investigate the molecular
mechanisms of drug resistance of those clinical resistant
isolates.
Recently, triazoles have been developed as the new savior
to the issue of drug resistance in Candida infection. Nev-
ertheless,  C. glabrata exhibits variable cross-resistance
among triazoles [9,18,23]. Thus, amphotericin B appears
to be the choice for treating systemic infections caused by
this species. However, along with the increased use of
amphotericin B, 20% and 36% of C. glabrata isolates from
North America and Latin America, respectively, were
reported to be resistant [23]. These data suggest that co-
resistance to amphotericin B and fluconazole of C. gla-
brata species may become a problem for clinical therapy
worldwide. In our study, we found only three C. glabrata
isolates resistant to amphotericin B, which is lower than
what has been reported. In that study, 20% of C. glabrata
causing candidemia collected in Taiwan in 2003 were
resistant to amphotericin B [16]. Coincidently, more C.
glabrata isolates in the TSARY 2002 (78.9%) had the MICs
of amphotericin B at 1 µg/ml than that in the TSARY 1999
(30.5%). Hence, periodic surveillance is needed to closely
monitor the trends of susceptibility to antifungal drugs
and for early detection of the newly emerging co-resist-
ance to amphotericin B and fluconazole of Candida spe-
cies, especially, of C. glabrata.
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